Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA.

Gene Editing 235

Gene Editing Gene DNA Gene Therapy 235

pharmaphorum

APRIL 27, 2021

Nevertheless it’s a relief for uniQure and other gene therapy developers, as there is a perennial concern that inserting genes into the genomes of patient cells could inadvertently activate genes that cause cancer. If a causal link had been established with the HCC case, it would have sent a shockwave across the sector.

Gene Therapy 52

Gene Therapy Gene Genome Genomics 52

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. The established method for this process is a triple transfection using three different DNA plasmids. More efficient, suspension-based cell culture processes are urgently needed in the now fast-developing genomic medicine space.

Genome 244

Genome Genomics Medicine Gene Therapy 244

The Pharma Data

OCTOBER 14, 2020

Assistant Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons, is designed to generate DNA aptamer-based anti-idiotypes to selected monoclonal antibodies identified in Dr. Ilya Trakht’s study. The study led by Dr. Sergei Rudchenko, Ph.D., 1 Noyce RS, et al. 2018) PLoS One. 13(1):e0188453.

Vaccine 40

Vaccine Vaccination Development Medicine 40

The Pharma Data

APRIL 30, 2021

a leading clinical-stage CRISPR genome editing biotechnology company, announced that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. AbbVie and Caribou Biosciences, Inc.,

Botox 40

Botox Production Development Cosmetics 40

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Its primary focus is on oncology, cardiovascular, immunology, and fibrotic therapeutic projects.

Antibody 130

Antibody DNA Genome Genomics 130

pharmaphorum

OCTOBER 1, 2021

Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 It may also use the cash injection for “in-licensing opportunities and potential acquisitions”, according to the document.

Marketing 52

Marketing Genome Genomics Business Development 52